DR. SHIRIT EINAV, MD
Osteopathic Medicine in Palo Alto, CA
License number
California A81396
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
269 Campus Dr Ccsr Building RM 3115, Palo Alto, CA 94305
Phone
(650) 498-7419
Organization information
See more information about SHIRIT EINAV at bizstanding.comShirit Einav MD,BA
269 Campus Dr, Stanford, CA 94305
Industry:
Internist
Phone:
(650) 498-7419 (Phone)
Description:
There is 1 doctor at this site. Surgery is not performed at this site.
Shirit Einav
Shirit Einav MD
300 Pasteur Dr, Stanford, CA 94305
Categories:
Infectious Disease Physicians & Surgeons, Internal Medicine Physicians & Surgeons
Phone:
(650) 723-4000 (Phone)
Professional information
Dr. Shirit Einav, Stanford CA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
300 Pasteur Dr STE S127, Stanford 94305
(650) 724-5243 (Phone), (650) 723-3474 (Fax)
STANFORD UNIVERSITY SCHOOL OF MEDICINE
300 Pasteur Dr STE S101, Stanford 94305
(650) 725-5071 (Phone)
269 Campus Dr STE 3115, Stanford 94305
(650) 498-7419 (Phone)
(650) 724-5243 (Phone), (650) 723-3474 (Fax)
STANFORD UNIVERSITY SCHOOL OF MEDICINE
300 Pasteur Dr STE S101, Stanford 94305
(650) 725-5071 (Phone)
269 Campus Dr STE 3115, Stanford 94305
(650) 498-7419 (Phone)
Certifications:
Infectious Disease, 2006, Internal Medicine, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Tel Aviv University / Sackler Faculty of Medicine
Tel Aviv University / Sackler Faculty of Medicine
Shirit Einav, Stanford CA
Specialties:
Infectious Disease Specialist
Address:
269 Campus Dr, Stanford, CA 94305
300 Pasteur Dr, Palo Alto, CA 94304
300 Pasteur Dr, Palo Alto, CA 94304
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)
Methods Of Treating A Flaviviridae Family Viral Infection, Compositions For Treating A Flaviviridae Family Viral Infection, And Screening Assays For Identifying Compositions For Treating A Flaviviridae Family Viral Infection
US Patent:
2010026, Oct 14, 2010
Filed:
Sep 18, 2008
Appl. No.:
12/678014
Inventors:
Stephen R. Quake - Stanford CA, US
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Wenjin Yang - Forster City CA, US
Doron Gerber - Mountain View CA, US
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Wenjin Yang - Forster City CA, US
Doron Gerber - Mountain View CA, US
International Classification:
A61K 38/21, A61K 31/4184, A61K 31/137, A61K 31/4025, A61K 31/4406, A61K 31/17, G01N 33/566, A61P 31/14
US Classification:
424 857, 514394, 514653, 514409, 514357, 514597, 436501
Abstract:
Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.
Methods And Compositions For Identifying Anti-Hcv Agents
US Patent:
2010020, Aug 12, 2010
Filed:
Jul 27, 2009
Appl. No.:
12/510150
Inventors:
JEFFREY S. GLENN - PALO ALTO CA, US
SHIRIT EINAV - STANFORD CA, US
MENASHE ELAZAR - PALO ALTO CA, US
SHIRIT EINAV - STANFORD CA, US
MENASHE ELAZAR - PALO ALTO CA, US
International Classification:
C12Q 1/70, C12Q 1/68, C12Q 1/34
US Classification:
435 5, 435 6, 435 18
Abstract:
The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.
Methods And Compositions For Identifying Agents That Inhibit An Ns4B-Mediated Neoplastic Cellular Phenotype Of Hcv Infected Cells
US Patent:
2009008, Mar 26, 2009
Filed:
Jun 20, 2008
Appl. No.:
12/143630
Inventors:
Jeffrey S. Glenn - Palo Alto CA, US
Shirit Einav - Stanford CA, US
Shirit Einav - Stanford CA, US
International Classification:
A01K 67/00, C12Q 1/02, C12Q 1/70, C40B 40/02, C12N 5/00
US Classification:
800 10, 435 29, 435 5, 506 14, 435325
Abstract:
The disclosure provides methods and compositions for identifying agents that inhibit a neoplastic cellular phenotype mediated by the NS4B protein nucleotide binding motif (NBM) of hepatitis C virus (HCV). In general, the methods involve contacting a candidate agent with a mammalian cell expressing an NS4B NBM polypeptide of an HCV virus, wherein expression of the NS4B NBM polypeptide in the absence of candidate agent promotes a neoplastic cellular phenotype, and detecting the presence or absence of an effect of said candidate agent on NS4B-mediated promotion of a neoplastic cellular phenotype. The disclosed methods and compositions find use in a variety of therapeutic and screening applications.
Methods And Compositions For Identifying Anti-Hcv Agents
US Patent:
2006019, Sep 7, 2006
Filed:
Aug 18, 2004
Appl. No.:
10/528377
Inventors:
Jeffrey Glenn - Palo Alto CA, US
Shirit Einav - Stanford CA, US
Menashe Elazar - Stanford CA, US
Shirit Einav - Stanford CA, US
Menashe Elazar - Stanford CA, US
International Classification:
C12Q 1/70
US Classification:
435005000
Abstract:
The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.
Methods And Compositions Of Treating A Flaviviridae Family Viral Infection
US Patent:
2010002, Feb 4, 2010
Filed:
Mar 18, 2009
Appl. No.:
12/383030
Inventors:
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
International Classification:
A61K 38/21, A61K 31/4184, C07D 403/02, C07D 403/12, C07D 471/04, A61K 31/497, A61K 31/4439, A61K 31/708, A61P 31/12
US Classification:
424 857, 514394, 5483061, 544370, 546118, 51425406, 514303, 514 43
Abstract:
Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
Methods And Compositions Of Treating A Flaviviridae Family Viral Infection
US Patent:
2010001, Jan 21, 2010
Filed:
Mar 18, 2009
Appl. No.:
12/383071
Inventors:
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Wenjin Yang - Foster City CA, US
Ingrid C. Choong - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
International Classification:
A61K 38/21, A61K 31/416, C12N 5/00, C07D 231/56, C07D 401/12, A61K 31/454, A61P 31/12, C07D 403/12
US Classification:
424 857, 514403, 435377, 424 854, 5483611, 546199, 514322
Abstract:
Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.
Methods Of Treating A Flaviviridae Family Viral Infection And Compositions For Treating A Flaviviridae Family Viral Infection
US Patent:
2011005, Mar 3, 2011
Filed:
Sep 18, 2008
Appl. No.:
12/677989
Inventors:
Shirit Einav - Stanford CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Wenjin Yang - Foster City CA, US
Jeffrey S. Glenn - Palo Alto CA, US
Robert McDowell - San Francisco CA, US
Wenjin Yang - Foster City CA, US
International Classification:
A61K 38/21, A61K 31/4184, A61K 31/7076, A61K 31/437, A61K 31/4985, A61K 31/52, A61K 31/415, A61K 31/404, A61K 31/55, A61P 31/14
US Classification:
424 857, 514394, 514 43, 514303, 514302, 514249, 5142631, 5142601, 514406, 514415, 51421709
Abstract:
Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of treating HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.